AZD5153 enhances the chemo-sensitivity of gemcitabine on pancreatic cancer cells in vitro and in vivo

Abstract Background Pancreatic cancer is a malignant disease with a poor prognosis. Gemcitabine (GEM), the first-line treatment drug, shows limited efficacy because of the notorious drug resistance of pancreatic cancer. Therefore, the development of sensitive drugs for pancreatic cancer is essential...

Full description

Bibliographic Details
Published in:Cancer Cell International
Main Authors: Haixin Zhu, Minmin Shen, Yiqian Zhu, Ruoqi Wang, Rong Dong, Yuyu Huang, Lulin Zhu, Ying Li, Youyou Yan, Jiang Lou, Bo Zhang, Nengming Lin, Biqin Tan
Format: Article
Language:English
Published: BMC 2025-08-01
Subjects:
AZD5153
Gemcitabine
Pancreatic cancer
ERK/mTOR signaling
MUC2
Online Access:https://doi.org/10.1186/s12935-025-03952-2

Internet

https://doi.org/10.1186/s12935-025-03952-2

Similar Items